跳至主要内容
临床试验/CTRI/2025/09/094449
CTRI/2025/09/094449尚未招募不适用

Comparative evaluation of aparveerataradi tailam matra basti and aparveerataradi tailam matra basti along with arkapushpikalka ghanvati in ashmari (urolithiasis)

Uttarakhand Ayurved University1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年9月28日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
36
试验地点
1
主要终点
Outcome will be measured by parameters :

研究概览

简要总结

Selected Drug :  Arkapushpikalka Ghanvati and Aparveerataradi Tailam

 Form of medicine: Arkapushpikalka will be given in the form of ghanvati and Aparveerataradi Tailam  will be given in the form of Matra Basti as explained in classical text.

Composition of medicine :

ARKAPUSHPIKALKA GHANVATI  : - 1. Shweta Arka Pushpi panchang

  1. Godugdh

APARVEERATARADI TAILAM :-         Pashanbhed

1.Veervruksh Bark  2. Pashanbhed Panchang 3. Arani Root Bark, Leaves 4. Shyonaka Root Bark  5. Patla Root Bark 6. Vrikshadani Whole Plant 7. Eranda Leaves, Root 8. Vetra Root 9. Swarnkshiri Panchang 10. Usher Mool 11. Padmak Seeds And Bark 12. Kusha Mool 13. Kaas Mool 14. Shar Mool 15. Kshudra Agnimantha Root Bark 16. Ikshu Mool 17. Aparajita Panchang 18. Kokilaksha Seeds 19. Shatavari Mool 20. Gokshur Seeds 21. Kapotvanka Panchang 22. Itkat Flowers, Leaves 23. Gambhari Mool

Preparation of medicine:- Arkapushpikalka Ghanvati and Aparveerataradi Tailam matra Basti will be prepared according to classical views.

Dose of medicine :- Arkapushpikalka Ghanvati - 1 Tablet BD [500 mg]

Aparveerataradi Tailam Matra Basti – 30 ml for 21 days

Route of Administration :- Ghan vati – oral

Matra Basti – Per Rectal

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
16.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Classical symptoms of Ashmari.
  • 2.Radiological evidence of calculus (up to 8 mm) in kidney, ureter, urinary bladder & urethra 3.Patients of both sex, irrespective of religion, socioeconomic status and occupation will be taken.

排除标准

  • Pregnant women and lactating mothers will be excluded 2.Calculi of size more than 8 mm. 3.Patients of Ashmari having systemic diseases like RHD, AIDS and Hepatitis B. 4.Complications related to Kidneys/ Ureter / Bladder like.
  • Acute Renal failure.
  • Chronic Renal Failure, Polycystic Kidney diseases, Impaired Renal function, etc. 6.Patients having moderate or severe Hydronephrosis will be excluded.

结局指标

主要结局

Outcome will be measured by parameters :

时间窗: Outcome will be evaluated every 7th day for 3 weeks

1 Pain

时间窗: Outcome will be evaluated every 7th day for 3 weeks

2. Burning Micturition

时间窗: Outcome will be evaluated every 7th day for 3 weeks

3. Dysuria

时间窗: Outcome will be evaluated every 7th day for 3 weeks

4. Frequency of Micturition

时间窗: Outcome will be evaluated every 7th day for 3 weeks

5. Hematuria

时间窗: Outcome will be evaluated every 7th day for 3 weeks

次要结局

  • 1. No. of calculi on the basis of USG KUB(2. Size of calculus ( acc. to USG before and after treatment))

研究者

发起方
Uttarakhand Ayurved University
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Vishal Verma

Rishikul Campus, Uttarakhand Ayurved University, Haridwar

研究点 (1)

Loading locations...

相似试验

Comparative evaluation of aparveerataradi oil enema... | 临床试验